What’s The Plan? US FDA Drug Development Tool Qualification Process Requires “Cultural Change”

FDA sees negotiating formal “qualification plan” as key process improvement that should ultimately accelerate pace for construction of biomarkers and other drug development tools. But it will take some getting used to.

Binoculars hang on a wooden fence background
Sponsors and the US FDA are going to need to change the way they look at biomarker development.

More from Clinical Trials

More from R&D